Jubilant Pharmova Reports Strong Financial Growth Amid Evaluation Adjustment in May 2025

Jubilant Pharmova, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 16, 2025, indicate a notable shift in the company's evaluation, with a revision in its score from 26 to 20 over the past three months. The financial performance for this quarter showcases several positive developments. Profit Before Tax less Other Income (PBT) reached Rs 197.40 crore, reflecting a significant year-on-year growth of 95.83%. This upward trend in PBT is complemented by an impressive Operating Profit to Interest ratio, which stands at 6.55 times, marking the highest level in the last five quarters. Additionally, Profit After Tax (PAT) amounted to Rs 156.02 crore, demonstrating a year-on-year increase of 41.5%. Net Sales also hit a peak at Rs 1,928.80 crore, while Operating Profit (PBDIT) reached Rs 345.40 crore, both representing the highest figures in the last five quarters. The Operating Profit Margin improved to 17.91%, indicating enhanced operational efficiency. Overall, Jubilant Pharmova's recent financial results reflect a series of positive trends, despite the adjustment in its evaluation. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.